These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

190 related articles for article (PubMed ID: 29805146)

  • 1. Challenges in the Regulation of Autologous Stem Cell Interventions in the United States.
    Sipp D
    Perspect Biol Med; 2018; 61(1):25-41. PubMed ID: 29805146
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The US Direct-to-Consumer Marketplace for Autologous Stem Cell Interventions.
    Turner L
    Perspect Biol Med; 2018; 61(1):7-24. PubMed ID: 29805145
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Vulnerabilities and the Use of Autologous Stem Cells for Medical Conditions in Australia.
    Hendl T
    Perspect Biol Med; 2018; 61(1):76-89. PubMed ID: 29805149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Direct-to-consumer stem cell marketing and regulatory responses.
    Sipp D
    Stem Cells Transl Med; 2013 Sep; 2(9):638-40. PubMed ID: 23934911
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The deadly business of an unregulated global stem cell industry.
    Lysaght T; Lipworth W; Hendl T; Kerridge I; Lee TL; Munsie M; Waldby C; Stewart C
    J Med Ethics; 2017 Nov; 43(11):744-746. PubMed ID: 28356490
    [TBL] [Abstract][Full Text] [Related]  

  • 6. FDA's claims over stem cells upheld.
    Cyranoski D
    Nature; 2012 Aug; 488(7409):14. PubMed ID: 22859178
    [No Abstract]   [Full Text] [Related]  

  • 7. The Need for Beneficence and Prudence in Clinical Innovation with Autologous Stem Cells.
    Lipworth W; Stewart C; Kerridge I
    Perspect Biol Med; 2018; 61(1):90-105. PubMed ID: 29805150
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Federal Regulatory Oversight of US Clinics Marketing Adipose-Derived Autologous Stem Cell Interventions: Insights From 3 New FDA Draft Guidance Documents.
    Turner LG
    Mayo Clin Proc; 2015 May; 90(5):567-71. PubMed ID: 25939934
    [No Abstract]   [Full Text] [Related]  

  • 9. US clinics marketing unproven and unlicensed adipose-derived autologous stem cell interventions.
    Turner LG
    Regen Med; 2015 May; 10(4):397-402. PubMed ID: 26022761
    [No Abstract]   [Full Text] [Related]  

  • 10. Rejuvenating Regenerative Medicine Regulation.
    Charo RA; Sipp D
    N Engl J Med; 2018 Feb; 378(6):504-505. PubMed ID: 29320637
    [No Abstract]   [Full Text] [Related]  

  • 11. Selling stem cell 'treatments' as research: prospective customer perspectives from crowdfunding campaigns.
    Snyder J; Turner L
    Regen Med; 2018 Jun; 13(4):375-384. PubMed ID: 29985757
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Allowing innovative stem cell-based therapies outside of clinical trials: ethical and policy challenges.
    Hyun I
    J Law Med Ethics; 2010; 38(2):277-85. PubMed ID: 20579251
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Food and Drug Administration, regenerative sciences, and the regulation of autologous stem cell therapies.
    von Tigerstrom B
    Food Drug Law J; 2011; 66(4):479-506, i. PubMed ID: 24505826
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identity and ownership issues in the regulation of autologous cells.
    Sipp D
    Regen Med; 2017 Oct; 12(7):827-838. PubMed ID: 29115180
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Regulatory and policy tools to address unproven stem cell interventions in Canada: the need for action.
    Caulfield T; Murdoch B
    BMC Med Ethics; 2019 Aug; 20(1):51. PubMed ID: 31383026
    [TBL] [Abstract][Full Text] [Related]  

  • 16. FDA challenges stem-cell clinic.
    Cyranoski D
    Nature; 2010 Aug; 466(7309):909. PubMed ID: 20725009
    [No Abstract]   [Full Text] [Related]  

  • 17. Challenging the FDA's authority to regulate autologous adult stem cells for therapeutic use: Celltex therapeutics' partnership with RNL Bio, substantial medical risks, and the implications of United States v. Regenerative Sciences.
    Drabiak-Syed K
    Health Matrix Clevel; 2013; 23(2):493-535. PubMed ID: 24341080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The FDA and the US direct-to-consumer marketplace for stem cell interventions: a temporal analysis.
    Knoepfler PS; Turner LG
    Regen Med; 2018 Jan; 13(1):19-27. PubMed ID: 29327974
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stem-cell-derived products: an FDA update.
    Moos M
    Trends Pharmacol Sci; 2008 Dec; 29(12):591-3. PubMed ID: 18937983
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ethical and Regulatory Challenges with Autologous Adult Stem Cells: A Comparative Review of International Regulations.
    Lysaght T; Kerridge IH; Sipp D; Porter G; Capps BJ
    J Bioeth Inq; 2017 Jun; 14(2):261-273. PubMed ID: 28247202
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.